Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05140382 · OUTCOME

Complete Response (CR) Rate

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL · Source last updated 2024-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
From Screening (Day -30 to Day-1) until disease progression or survival until death (26 months).

What was measured

Complete response rate is defined as proportion of participants who have a complete response according to the Lugano (2014) response criteria.

Analysis population: Response evaluable set included all dosed participants who had measurable disease at baseline.

Groups in this outcome

Cohort 1 Non-NK PTCL

Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.

Cohort 2 NK PTCL

Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.

Cohort 3 cHL

Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 1 Non-NK PTCL31
Cohort 2 NK PTCL2
Cohort 3 cHL19

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 1 Non-NK PTCL19.4Not reportedNot reportedNot reportedNot reported
Cohort 2 NK PTCL0Not reportedNot reportedNot reportedNot reported
Cohort 3 cHL15.8Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        19.4
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        15.8
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    2. group Id
      OG001
      value
      2
    3. group Id
      OG002
      value
      19
    units
    Participants
description
Complete response rate is defined as proportion of participants who have a complete response according to the Lugano (2014) response criteria.
groups
  1. description
    Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
    id
    OG000
    title
    Cohort 1 Non-NK PTCL
  2. description
    Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
    id
    OG001
    title
    Cohort 2 NK PTCL
  3. description
    Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.
    id
    OG002
    title
    Cohort 3 cHL
param Type
NUMBER
population Description
Response evaluable set included all dosed participants who had measurable disease at baseline.
reporting Status
POSTED
time Frame
From Screening (Day -30 to Day-1) until disease progression or survival until death (26 months).
title
Complete Response (CR) Rate
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice